Bolden Therapeutics is developing first-in-class therapeutics to increase neurogenesis (the formation of new brain cells) and improve outcomes in neurological disease.
Bolden has established proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory in a proprietary mouse model targeting a novel and specific signaling pathway.
Bolden is developing multiple therapeutic modalities in parallel, leading with exon-skipping antisense oligonucleotides.
Due to the fundamental nature of neurogenesis, there are several potential clinical applications for neurogenesis-promoting therapies, such as those we aim to develop.
Bolden has a strong and growing team with complementary expertise.
Ana is currently a fifth-year Chemical Engineering student with a minor in Biochemical Engineering at Northeastern University. She has done two co-ops while at Northeastern. The first one was at Nano-C, a nanotechnology company that specializes in carbon nanotubes. Her second co-op was at Pfizer in their Upstream Process Development branch. At Northeastern, she is a member of Hispanic Student Unity, Northeastern CUP, and the American Institute of Chemical Engineers (AIChE). Ana is excited about joining Bolden and contributing to their research efforts in neurodegenerative diseases.
Andrea graduated with a B.S. in Cellular, Molecular and Biomedical Biology from Boise State University (BSU) Cum Laude in May 2022. She researched gut microbiota composition changes in mice correlated with Influenza, MRSA and Oseltamivir treatment, for the Idaho Veterans Research Education Foundation (IVREF). As a BSU research intern Andrea developed working prototypes to visualize and document plant fluorescence in a field setting, for the Forbey Lab. Currently Andrea is a Station1 Frontiers Fellow interning here at Bolden Therapeutics contributing to our understanding of the complex relationship between neurogenesis and disease states.
Dr. Valat completed a double MSc program from the Université Grenoble Alpes (France), one in Bioengineering, biomedical instrumentation and implantable biomaterials, and the other in Nanosciences and nanobiotechnology. She also completed her PhD in biomaterials and biomechanics also from the Université Grenoble Alpes. She carried out her postdoctoral research at in the Kaplan Lab at Tufts University, working on combining cellular therapy and silk-based materials for the treatment of neurodegenerative diseases.
Dr. Webb is a Scientific Founder of Bolden Therapeutics. She completed her undergraduate degree with honors in Biology at McGill University in and her PhD in Molecular and Cell Biology at University of Washington and postdoctoral work at Stanford. Dr. Webb now holds the Richard and Edna Salomon Assistant Endowed Professorship of Molecular Biology, Cell Biology, and Biochemistry at Brown University. Dr. Webb’s expertise is in neural stem cell homeostasis and cellular mechanisms of aging.
Dr. Polsky is the Executive Chairman of Bolden Therapeutics, Inc. He is an experienced investor and proven business leader in the life science spectrum. Most recently, as CEO of William Harris Investors, Dr. Polsky oversaw and managed a $1B family office. He has spent the past 18 years investing in everything from early-stage venture biotech through international large-cap vertically-integrated pharmaceutical companies. In addition to Dr. Polsky’s oversight and investing activities, he has also been a corporate board member of nearly a dozen companies and a member of the Investment Committee for the University of Chicago’s Innovation Fund. Dr. Polsky provides critical guidance for Bolden Therapeutics as it continues to advance its mission of addressing cognitive dysfunction in neurological diseases through the development of novel therapeutic drugs.
Emma is currently a 3rd year biomedical engineering major at Tufts University. Before coming to Bolden, Emma took the year off from school to do Tufts' co-op program. Her first co-op was at Insulet working as a systems engineer, and she just finished her second co-op at Moderna working on the Lipid Nanoparticle Process Development team. Back at school, she is a member in the Society of Women Engineers (SWE), a group leader for Tufts Engineering Ambassadors, a Girls in STEM mentor, an LCS tutor, and a member of Tufts Mountain Club. Additionally, Emma was recently inducted into the Tau Beta Pi Engineering Honor Society and was the 2021 recipient of the Lt. Commander Robert James Manning Memorial Prize. Now Emma is looking forward to trying her hand at research and contributing to the efforts surrounding neurodegenerative disease.
Joel earned an A.S. in Biomedical Engineering (BME) at Bunker Hill Community College (BHCC) in May 2022. He is a rising junior student currently pursuing a B.S. in BME at Cornell University. Joel successfully conducted four different honors research projects, including a biopsychology research project, at BHCC as a Commonwealth Honors Program (CHP) member of Massachusetts and a biomaterial-based cancer vaccine research project in Dr. Mooney’s Lab at Harvard University. With his undergraduate independent honors research project on melanoma, he was awarded as one of the two top research poster presenters at the first BHCC Honors Research Project Contest conducted by the CHP. Furthermore, after preparing a literature review, an abstract, a PowerPoint research presentation, as well as a research poster presentation of his project performed at Harvard, he received the Annual Biomedical Research Conference for Minority Students (ABRCMS) 2021 Presentation Award and the American Association of Immunologists (AAI) 2022 Young Scholar Travel Award. Joel has been nominated as a student member of the American Association for Cancer Research and the AAI. He has a natural passion for revolutionizing human health through scientific research. Currently, Joel is part of the Station1 Frontiers Fellowship that is conducted by MIT scientists. As a Station1 Fellow, he is interning here at Bolden Therapeutics to contribute to the company’s research on neurological diseases and explore the scientific and social aspects of particular findings.
Johnny Page is a Co-Founder and CEO of Bolden Therapeutics. He received his A.B. in Music, Sc.B. in Neuroscience, and Sc.M. in Biotechnology, all from Brown University. He has completed two years of medical school at Alpert Medical School. Johnny has also completed additional entrepreneurship training as part of the I-Corps Spark Program at MIT. Johnny leads Bolden’s effort to develop novel compounds to help treat neurological diseases.
Dr. Fallon is a Scientific Founder of and the Chair of the Scientific Advisory Board of Bolden Therapeutics. He completed his undergraduate degree in Biology at Colgate University in and his PhD in Cell Biology at University of Pennsylvania with further training at University College London and Stanford. Throughout his career, Dr. Fallon has performed basic and translational research for many diseases, including muscular dystrophies, Fragile X syndrome, ALS, and Alzheimer’s disease. Previously, Dr. Fallon developed a recombinant protein therapeutic for treatment of Duchenne muscular dystrophy and founded Tivorsan Pharmaceuticals. For the past two decades, Dr. Fallon has been a full Professor of Neuroscience at Brown University.
Dr. Salloway received his MD from Stanford Medical School and completed residencies in neurology and psychiatry at Yale University. He is the Martin M. Zucker Professor of Psychiatry and Human Behavior, and Professor of Neurology at the Warren Alpert Medical School of Brown University, and Chief of Neurology and Director of the Memory and Aging Program at Butler Hospital. Dr. Salloway is an internationally recognized leader in clinical trials for the prevention and treatment of Alzheimer’s disease (AD). His program has conducted more than 100 clinical trials for AD and related disorders. He has chaired the Steering Committees for major AD pivotal trials and he has been a lead author for key publications in AD research in the New England Journal of Medicine, Nature and other top-tiered journals. He is the Past President of the American Neuropsychiatric Association, a Fellow of the American Academy of Neurology and a member of the American Neurological Association. He serves as a consultant for drug development to the NIH, the Alzheimer’s Association, the Alzheimer’s Drug Discovery Foundation and many other groups working on AD therapeutics. He has published more than 400 scientific articles and abstracts and edited 3 books and he lectures widely about the early diagnosis and prevention of AD.
Sudhir Agrawal, D. Phil, FRSC, is a Visiting Professor in the Department of Medicine at The University of Massachusetts Medical School, and a member of the Business Advisory Board of the Harvard Medical School’s Initiative for RNA Medicine. He is founder and member of ARNAY Sciences LLC. He is also a founder of Idera Pharmaceuticals and has had held various leadership roles within the company, including Chairman, CEO, President of Research, and Chief Scientific Officer. Over the last three decades, his research has been focused on the discovery and development of nucleic acid therapeutics, including antisense technology. He has published over 300 research papers and is listed as a co-inventor of more than 400 patents worldwide. He has edited four books on oligonucleotides and antisense technology, including a recent book on ‘Advances in Nucleic Acid Therapeutics’ published by the Royal Society of Chemistry.
Neurogenesis is the formation of new neurons from neural stem cells (NSCs). It is an endogenous process that has been observed throughout life into advanced age. NSCs reside in at least two regions of the adult brain: the dentate gyrus of the hippocampus and the subventricular zone, which lines the lateral ventricles. Additional information about neurogenesis, Alzheimer's disease, and drug development can be found in our team’s publications.
CAMBRIDGE, MA. Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced being awarded a Small Business Innovative Research (SBIR) grant for $497,500 from the National Institute on Aging (NIA) of the National Institutes of Health.
PROVIDENCE, RI & CAMBRIDGE, MA. Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for potential treatment ofCNS diseases such as Alzheimer’s disease, today announced receiving a $500,000 Phase I Small Business Technology Transfer (STTR) grant from the National Institute on Aging of the National Institutes of Health.
PROVIDENCE, RI. Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for potential treatment of CNS diseases such as Alzheimer’s and ischemic stroke, today announced being awarded the Biogen-LabCentral Golden Ticket.